GlassScriptPhysician profile
Roy D Blount
NPI 1922176817
$1,586.10
in general payments reported to CMS, 2019-2025
14 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $221 · 2022: $166 · 2023: $336 · 2024: $537 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,199.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $857.00 | 2021-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Nevro Corp. | $148.48 | 2021-2024 | Senza |
| Collegium Pharmaceutical, INC. | $138.62 | 2023-2025 | Belbuca, Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.34 | 2022-2024 | Relistor |
| Medtronic, INC. | $66.94 | 2021 | |
| Averitas Pharma INC. | $58.32 | 2023-2025 | Qutenza |
| Nalu Medical, INC. | $50.55 | 2021 | |
| Grt US Holding, INC. | $33.77 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $33.62 | 2023-2024 | Horizant, Horizant |
| Biodelivery Sciences International, INC. | $27.66 | 2021 | |
| Si-Bone, INC. | $24.52 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $20.65 | 2023 | Zilretta, Iovera |
| Ibsa Pharma INC. | $13.56 | 2021 | |
| Redhill Biopharma INC. | $13.07 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Blount listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.